My lab initiated gene delivery based cancer immune therapy 20 years ago when I started my first job. My lab has received issued patents and licenses for multiple of our products during this period. Though multiple factors impact the success of cancer immune therapy, an effective and clinical compatible delivery methods and the proper delivery sites/targets are critical for such a success. This seminar will try to summarize our work during the past 20 years. If time permits, I will also discuss the contribution of immune surveillance/impression systems on tumor initiation/progression.